Methods of treatment of cholestatic diseases
The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
1. A method for the treatment of primary biliary cholangitis, the method comprising orally administering elafibranor at a dose between 70 mg and 130 mg per administration to a subject with primary biliary cholangitis.
2. The method according to claim 1 , wherein the subject is a patient with primary biliary cholangitis and inadequate response to ursodeoxycholic acid.
3. The method according to claim 1 , the method comprising orally administering once daily 80 or 120 mg/day of elafibranor.
4. The method according to claim 1 , the method comprising orally administering once daily 80 mg/day of elafibranor.
5. The method according to claim 1 , the method further comprising administering to the subject another anti-cholestatic agent.
6. A method for the treatment of primary biliary cholangitis, comprising orally administering elafibranor at a dose between 70 mg and 130 mg per administration in combination with ursodeoxycholic acid to a subject with primary biliary cholangitis and inadequate response to ursodeoxycholic acid.
7. The method according to claim 6 , wherein elafibranor is administered at a dose of 80 mg per administration.
8. The method according to claim 6 , wherein elafibranor is orally administered once daily at a dose of 80 mg/day.
9. The method according to claim 6 , wherein elafibranor is administered at a dose of 120 mg per administration.
10. The method according to claim 6 , wherein elafibranor is orally administered once daily at a dose of 120 mg/day.
11. A method for the treatment of primary biliary cholangitis, comprising orally administering 80 mg/day of elafibranor once daily in combination with ursodeoxycholic acid to a subject with primary biliary cholangitis and inadequate response to ursodeoxycholic acid.